Published in Clin Infect Dis on October 20, 2015
Spatial Distribution of Mycobacterium ulcerans in Buruli Ulcer Lesions: Implications for Laboratory Diagnosis. PLoS Negl Trop Dis (2016) 0.75
ImageJ for microscopy. Biotechniques (2007) 13.89
Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science (1999) 6.37
Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet (2010) 5.02
Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am J Trop Med Hyg (1998) 3.24
Mycobacterium ulcerans disease (Buruli ulcer) in rural hospital, Southern Benin, 1997-2001. Emerg Infect Dis (2004) 3.08
Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol (2009) 1.77
Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis (2011) 1.58
Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis (2011) 1.51
Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis (2010) 1.48
Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun (2004) 1.48
Geographic distribution, age pattern and sites of lesions in a cohort of Buruli ulcer patients from the Mapé Basin of Cameroon. PLoS Negl Trop Dis (2013) 1.42
Mycobacterium ulcerans disease (Buruli ulcer) in a rural hospital in Bas-Congo, Democratic Republic of Congo, 2002-2004. Am J Trop Med Hyg (2006) 1.42
Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother (2013) 1.27
Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin Biol Ther (2009) 1.18
Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg (1974) 1.14
Long term streptomycin toxicity in the treatment of Buruli Ulcer: follow-up of participants in the BURULICO drug trial. PLoS Negl Trop Dis (2014) 1.06
Direct detection of Mycobacterium ulcerans in clinical specimens and environmental samples. Methods Mol Biol (2013) 1.04
Phase change material for thermotherapy of Buruli ulcer: a prospective observational single centre proof-of-principle trial. PLoS Negl Trop Dis (2009) 1.00
Spontaneous clearance of a secondary Buruli ulcer lesion emerging ten months after completion of chemotherapy--a case report from Togo. PLoS Negl Trop Dis (2012) 0.97
Primary cultivation: factors affecting contamination and Mycobacterium ulcerans growth after long turnover time of clinical specimens. BMC Infect Dis (2014) 0.97
Buruli-ulcer induced disability in ghana: a study at apromase in the ashanti region. Plast Surg Int (2012) 0.96
Multicenter external quality assessment program for PCR detection of Mycobacterium ulcerans in clinical and environmental specimens. PLoS One (2014) 0.80
Novel low-cost thermotherapy for cutaneous leishmaniasis in Peru. PLoS Negl Trop Dis (2013) 0.79
Phase change material for thermotherapy of Buruli ulcer: modelling as an aid to implementation. J Med Eng Technol (2009) 0.78
Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women ('Option B+') in Malawi. AIDS (2014) 5.43
Hepatitis B viral load in dried blood spots: A validation study in Zambia. J Clin Virol (2015) 0.83
Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study. Vaccine (2014) 0.83